AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03585426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections.
Study NCT01885182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone
Study NCT01885182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Study NCT01431443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavanol-rich chocolate
Description: The aim of this study is to evaluate the beneficial effect of dark chocolate consumption through the activity of flavanols on the endothelial function and blood pressure regulation, in acute (after 3 hours) and chronic effect (12 weeks), among pregnant women at high risk for preeclampsia.
Study NCT01431443 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Chocolate
Description: Placebo intervention
Study NCT01997294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sequential therapy of atorvastatin
Description: 80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
Study NCT03072121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium
Description: 10 mg tablet, two tablets each night.
Study NCT03072121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isosorbide Mononitrate Tab 20 MG
Description: 1 tablet two times daily.
Study NCT01997294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential therapy of atorvastatin
Description: 80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
Study NCT00975741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OXIMAX
Study NCT00975741 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ASMANEX TWISTHALER
Study NCT04532398 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gugging swallowing screen - ICU (GUSS-ICU) index test
Description: Gugging swallowing screen - ICU (GUSS-ICU) index test:~Screening for post-extubation dysphagia: GUSS-ICU performed by 2 speech therapists independently. The GUSS-ICU model contains the core features of the original GUSS tool with the added assessment items specific to the ICU Patient (RASS score (Richmond Agitation and Sedation Scale)).~Stage one of the screen focuses on the preliminary investigation of indirect swallowing. Stage two is comprised of varying steps that directly test swallowing. This would include the administration of semisolids, water and bread with four distinct signs that were being assessed for - deglutition, coughing, drooling and voice change. The GUSS test is evaluated using a points system (0-10) which determines the severity of dysphagia and recommends a diet form that largely minimizes the risk of aspiration. (e.g. 10 points: No dysphagia = normal food).
Study NCT04532398 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Flexible Endoscopic Evaluation of Swallowing (FEES) reference test
Description: Flexible Endoscopic Evaluation of Swallowing (FEES) reference test:~Flexible Endoscopic Evaluation of Swallowing (FEES) is a technique to directly view the pharynx, larynx and esophagus during swallowing. The swallowing test is carried out first with saliva and then with different consistency (liquid, pulpy, solid) and different sized swallowing portions. This reference test is performed independently from the GUSS-ICU index test.
Study NCT00172419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin, 40 mg/day for 12 weeks
Study NCT03059485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC/AML Fusion Vaccine
Description: The Dendritic Cell Fusion Vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells
Study NCT03059485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Traditional care provided by the hospital.
Study NCT00305916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multislice spiral computed tomography coronary angiography
Study NCT00305916 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional coronary angiography
Study NCT02451150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan tablets
Study NCT01568749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol Formulation 2
Description: Paracetamol
Study NCT01568749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol formulation 3
Description: Paracetamol
Study NCT01568749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol formulation 4
Description: paracetamol
Study NCT04178109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen/tramadol (27mg/75mg)
Description: Postoperatively patients in Group A received the oral combination dexketoprofen/tramadol for the treatment of acute postoperative pain the first 72h
Study NCT04178109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol hydrochloride
Description: Patients in group B received IV tramadol 75mg every 8h
Study NCT04178109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: Patients in group B received IV paracetamol 1g every 8h
Study NCT04178109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hydrochloride 7.5 MG/ML
Description: 300mg ropivacaine as periarticular injection in a dilution of 100ml n/s 0,9% was done by the orthopedic surgeon in all patients
Study NCT04178109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine Hydrochloride 7.5 MG/ML
Description: 300mg ropivacaine as periarticular injection in a dilution of 100ml n/s 0,9% was done by the orthopedic surgeon in all patients
Study NCT04178109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride
Description: 10-15mg levobupivacaine was done subarachnoidal for spinal anesthesia
Study NCT04178109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine Hydrochloride
Description: 10-15mg levobupivacaine was done subarachnoidal for spinal anesthesia
Study NCT01717794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thunderbeat technology
Study NCT01717794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard bipolar electrosurgery
Study NCT06420713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Horizontal Bone Augmentation of Alveolar Ridge
Description: Elevation of the flap in the anterior region of atrophic maxilla to receive particulate autogenous bone mixed with deproteinized bovine bone graft (Group A) or Leukocyte-and-Platelet-Rich Fibrin (L-PRF) mixed with deproteinized bovine bone graft (Group B). In both groups, bone augmentations were covered with a collagen membrane stabilized with pins.
Study NCT06420713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Groups
Description: The patients underwent Guided Bone Regeneration (GBR) procedures for the reconstruction of atrophic edentulous alveolar ridges and were divided into two groups according to the proposed treatment:~Group A - GBR using a mixture of particulate autogenous bone graft and deproteinized bovine bone graft (Bio-Oss® Small; Geistlich AG, Wolhusen, Switzerland).~Group B - GBR using a mixture of deproteinized bovine bone graft (Bio-Oss® Small) and L-PRF + Liquid Fibrinogen.
Study NCT06420713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implants
Description: After 8 months of GBR healing, dental implants were placed in the grafted regions using guided surgery techniques.~Cone beam computed tomography (CBCT) scans were performed preoperatively, immediately after the surgical procedure, and after 8 months of follow-up to measure the linear and volumetric changes in the alveolar ridge. At the time of dental implant placement, after an 8-month period following the GBR procedures, bone biopsies were obtained from the grafted area for histological and micro-CT analysis.~The stability of the implants was assessed using resonance frequency analysis in the immediate postoperative period and at 6 months postoperatively.~After the 6-month period following dental implant placement, the patients were cleared for implant-supported prosthetic rehabilitation.
Study NCT01103219 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition
Description: The control (placebo) group will be fed according to the routines of the participating institutions. The intervention (active) group will receive increased supply of energy, protein, vitamin A and long-chain unsaturated fatty acids.
Study NCT01103219 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: The control (placebo) group will be fed according to the routines of the participating institutions. The intervention (active) group will receive increased supply of energy, protein, vitamin A and long-chain unsaturated fatty acids.
Study NCT01552304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Description: Besides perioperative routine care provided by anesthesiologists and surgeons, patients will receive postoperative oxygen supplementation with nasal prolong at 3 liters/min during the first 3 nights after surgery.
Study NCT01552304 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Study NCT03109886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milciclib maleate
Description: 100 mg/day once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles) unless patient refusal, consent withdrawal, Investigator's decision, unacceptable toxicity or death whichever occurs earlier. After the completion of three cycles, patients who, in the Investigator's judgment, are benefiting from treatment with milciclib, will resume treatment and will remain on study up to Day 180 from treatment start, unless withdrawal criteria are met earlier.
Study NCT01990937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral midazolam
Description: 5 mg in 15 mL of apple juice, orally 30 minutes before undergoing EGD
Study NCT01413113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given PO
Study NCT01413113 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131
Description: Given IM
Study NCT02712411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1303
Study NCT02712411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1201
Study NCT02712411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1402
Study NCT02076919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHA510 Ophthalmic Suspension
Description: Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2
Study NCT02076919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LHA510 Vehicle
Description: Inactive ingredients used for masking purposes
Study NCT02786771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spire
Study NCT02786771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muse headband
Study NCT03899480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical Natural Killer (NK) Cells
Description: infusion with N-803 activated NK cells
Study NCT01977612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-0 monofilament suture
Description: Skin closure using 4-0 monofilament suture
Study NCT01977612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stainless steel staples
Description: Skin closure using stainless steel staples.
Study NCT04628286 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Laser
Description: Sham Laser in plantar fascia
Study NCT04628286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Induction
Description: Myofascial Induction in plantar fascia
Study NCT02071979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous PRP Gel
Description: Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then activated (by mixing with thrombin and calcium chloride) and sprayed directly on the area to be treated.
Study NCT02071979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous PRP Injections
Description: Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then drawn into multiple small syringes and injected directly into the wound bed or the skin surrounding it.
Study NCT02071979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous PRP Gel plus PRP Injections
Description: Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and PRP from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then divided into equal parts and half is drawn into multiple small syringes and injected directly into the skin surrounding the wound bed, half is activated (by mixing with thrombin and calcium chloride) and sprayed the wound bed.
Study NCT02071979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Wound Care
Description: Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices.
Study NCT03072121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate Tab 20 MG
Description: 1 tablet two times daily.
Study NCT03072121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoprolol Tartrate Tab 25 MG
Description: 12.5 mg or 25 mg two times daily.
Study NCT03072121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Tartrate Tab 25 MG
Description: 12.5 mg or 25 mg two times daily.
Study NCT03072121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trimetazidine Dihydrochloride Tablets
Description: 20 mg tablet, one tablet three times daily.
Study NCT03072121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine Dihydrochloride Tablets
Description: 20 mg tablet, one tablet three times daily.
Study NCT01944410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: injection of PRP to traumatic bone cyst defect
Study NCT04120051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented canola-seaweed
Description: A daily sachet with 5 gram FCS-granulate for 6 weeks
Study NCT04120051 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A daily sachet with 5 gram rye cereal for 6 weeks
Study NCT02516644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: 12 sessions of 1 hour (30 min of virtual reality and 30 min of aerobic exercise with treadmill training): three times a week over four weeks
Study NCT02516644 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: 12 sessions of 1 hour of conventional physiotherapy: three times a week over four weeks
Study NCT02599844 — intervention group
Intervention type: DRUG
Intervention: Iodohippurate
Description: An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
Study NCT02599844 — intervention group
Intervention type: PROCEDURE
Intervention: 24 hour ambulatory Blood Pressure
Description: Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
Study NCT02599844 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral Arterial Tonometry
Description: The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
Study NCT02599844 — intervention group
Intervention type: PROCEDURE
Intervention: Pulse Wave Velocity
Description: Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
Study NCT02599844 — intervention group
Intervention type: DRUG
Intervention: Gadolinium
Description: Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.
Study NCT04128436 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Taking blood samples for analyzing progesterone levels
Description: As part of standard in vitro fertilization treatment, Crinone gel will be used starting the next morning following the oocyte pick-up (OPU) as a luteal phase support. On the trigger day, on the day OPU+2/3 (early luteal phase) and on the embryo transfer day (OPU+5, mid luteal phase) blood samples will be taken from patients for evaluating the progesterone levels. Blood samples will be collected at the 6th hour following the morning dose of vaginal progesterone gel. No other intervention will be done to the patients.
Study NCT03311568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound for microcirculatory assessment
Description: Ultrasound for microcirculatory assessment Repeated measurements within study participants for analysis of variance and explorative analyses of ultrasound signals, to identify most suitable parameters to describe microcirculatory alterations in critical disease, especially in sepsis.~Analyse blood flow velocities in several depths and from several vessels of different sizes simultaneously~US registration repeated within each study participant consecutively on seven different regions of the body surface.
Study NCT00902044 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous HER2-specific T cells
Description: Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.
Study NCT04672772 — intervention group
Intervention type: DRUG
Intervention: Cetuximab
Description: Weekly cetuximab at starting dose, that could be switched to biweekly
Study NCT04672772 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel
Description: Paclitaxel at starting dose of 80 mg/m2
Study NCT04505813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEXI-002 T Cells
Description: The NEXI-001 T cell product will be administered as a single IV infusion to patients within 72 hours after completing LD therapy.
Study NCT01672619 — intervention group
Intervention type: PROCEDURE
Intervention: dynamic craniotomy
Description: Surgical technique of craniotomy spiral without detachment of dura mater
Study NCT02241668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: FLT Pet Scan performed about 60 minutes after 3'-Deoxy-3'-18f-Fluorothymidine solution injected.
Study NCT02241668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3'-Deoxy-3'-18f-Fluorothymidine
Description: 3'-Deoxy-3'-18f-Fluorothymidine solution injected through a central venous catheter after MRI scan. After solution injected into a vein, PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. Entire procedure should last about 60-70 minutes.
Study NCT00130819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-based substance abuse treatment with buprenorphine
Description: Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
Study NCT00130819 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case management and referred substance abuse treatment
Description: Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence